Wed, October 27, 2010
Tue, October 26, 2010
Mon, October 25, 2010
Sun, October 24, 2010
[ Sun, Oct 24th 2010 ] - Market Wire
Alcon Board Elects New Chairman
Sat, October 23, 2010
Fri, October 22, 2010
Thu, October 21, 2010
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ] - Market Wire
STJ, AGAM, BAC, MDT, BSX
Tue, October 19, 2010
Mon, October 18, 2010
Sun, October 17, 2010
Sat, October 16, 2010
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ] - Market Wire
ALGN, FCN, GOOG, SWY, GCI
Thu, October 14, 2010
Wed, October 13, 2010
Tue, October 12, 2010
Mon, October 11, 2010
[ Mon, Oct 11th 2010 ] - Market Wire
SNY,GENZ,LH,AVB,MU
[ Mon, Oct 11th 2010 ] - Market Wire
ARAY,SI,VAR,TOMO,JMBA
Sun, October 10, 2010
Sat, October 9, 2010
Fri, October 8, 2010
Thu, October 7, 2010
[ Thu, Oct 07th 2010 ] - Market Wire
30pm CST

Idera Pharmaceuticals to Present at the 17th Annual NewsMakers in the Biotech Industry Conference


//health-fitness.news-articles.net/content/2010/ .. wsmakers-in-the-biotech-industry-conference.html
Published in Health and Fitness on Monday, October 18th 2010 at 13:15 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the 17th Annual NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 2:30 p.m. ET at the Millennium Broadway Hotel & Conference Center in New York City.

The live audio webcast presentation will be available in the Investor section of the companya™s website at [ www.iderapharma.com ]. Archived replays will also be available on the companya™s site for two weeks following the event. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. The companya™s proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Ideraa™s pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit [ www.iderapharma.com ].


Publication Contributing Sources